Nonreceptor tyrosine kinases in prostate cancer

被引:101
|
作者
Chang, Yu-Ming
Kung, Hsing-Jien
Evans, Christopher P. [1 ]
机构
[1] Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Dept Biol Chem, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
来源
NEOPLASIA | 2007年 / 9卷 / 02期
关键词
nonreceptor tyrosine kinase; prostate cancer; Src; FAK; ETK;
D O I
10.1593/neo.06694
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP. Underscoring NRTK's and, specifically, Src's importance in cancer is the recent approval by the US Food and Drug Administration of dasatinib, the first commercial Src inhibitor for clinical use in chronic myelogenous leukemia (CML). In this review we will focus on NRTKs and their roles in the biology of CaP. MATERIALS AND METHODS: Publicly available literature from PubMed regarding the topic of members of NRTKs in CaP was searched and reviewed. RESULTS: Src, FAK, JaK1/2, and ETK are involved in processes indispensable to the biology of CaP: cell growth, migration, invasion, angiogenesis, and apoptosis. CONCLUSIONS: Src emerges as a common signaling and regulatory molecule in multiple biological processes in CaP. Src's relative importance in particular stages of CaP, however, required further definition. Continued investigation of NRTKs will increase our understanding of their biological function and potential role as new therapeutic targets.
引用
收藏
页码:90 / 100
页数:11
相关论文
共 50 条
  • [41] Differential Requirement for Src Family Tyrosine Kinases in the Initiation, Progression, and Metastasis of Prostate Cancer
    Gelman, Irwin H.
    Peresie, Jennifer
    Eng, Kevin H.
    Foster, Barbara A.
    MOLECULAR CANCER RESEARCH, 2014, 12 (10) : 1470 - 1479
  • [42] Tyrosine kinases, androgen receptor and prostate cancers.
    Kung, Hsing-Jien
    TUMOR BIOLOGY, 2006, 27
  • [43] Tyrosine kinases as targets for cancer therapy
    Krause, DS
    Van Etten, RA
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 172 - 187
  • [44] Significance of tyrosine kinases in cancer: overview
    Andersson, LC
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S2 - S2
  • [45] Tyrosine kinases as targets for cancer therapy
    Levitzki, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S11 - S18
  • [46] A History of Cancer Research: Tyrosine Kinases
    Lipsick, Joseph
    COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2019, 11 (02): : 19
  • [47] Uncoupling of nonreceptor tyrosine kinases from PLC-γ1 in an SLP-76-deficient T cell
    Yablonski, D
    Kuhne, MR
    Kadlecek, T
    Weiss, A
    SCIENCE, 1998, 281 (5375) : 413 - 416
  • [48] BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer
    Chen, Sen
    Cai, Changmeng
    Sowalsky, Adam G.
    Ye, Huihui
    Ma, Fen
    Yuan, Xin
    Simon, Nicholas I.
    Gray, Nathanael S.
    Balk, Steven P.
    CANCER RESEARCH, 2018, 78 (18) : 5203 - 5215
  • [49] CYMRIC, A NEW MEMBER OF THE SHARK FAMILY OF NONRECEPTOR TYROSINE KINASES, IS EXPRESSED DIFFERENTIALLY IN ASCIDIANS WITH ALTERNATE MODES OF DEVELOPMENT
    SWALLA, BJ
    MAKABE, KW
    SATOH, N
    JEFFERY, WR
    MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 500 - 500
  • [50] THE EPH FAMILY OF RECEPTOR TYROSINE KINASES AS TUMOR SUPPRESSORS IN AFRICAN-AMERICANS WITH PROSTATE CANCER
    Kim, Albert H.
    Nguyen, Jane
    Schluchter, Mark
    Wang, Bingcheng
    Nguyen, Carvell
    JOURNAL OF UROLOGY, 2018, 199 (04): : E372 - E372